Search Results - "Massutí Sureda, Bartomeu"

HER1/EGFR Inhibitor‐Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum by Pérez‐Soler, Román, Delord, Jean Pierre, Halpern, Allan, Kelly, Karen, Krueger, James, Sureda, Bartomeu Massutí, von Pawel, Joachim, Temel, Jennifer, Siena, Salvatore, Soulières, Denis, Saltz, Leonard, Leyden, James

“…Learning Objectives After completing this course, the reader will be able to: Describe the clinical and pathological characteristics of the cutaneous rash…”
Get full text

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study by Jantus-Lewintre, Eloisa, Massutí Sureda, Bartomeu, González Larriba, José Luis, Rodríguez-Abreu, Delvys, Juan, Oscar, Blasco, Ana, Dómine, Manuel, Provencio Pulla, Mariano, Garde, Javier, Álvarez, Rosa, Maestu, Inmaculada, Pérez de Carrión, Ramón, Artal, Ángel, Rolfo, Christian, de Castro, Javier, Guillot, Mónica, Oramas, Juana, de las Peñas, Ramón, Ferrera, Lioba, Martínez, Natividad, Serra, Òlbia, Rosell, Rafael, Camps, Carlos

“…Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the…”
Get full text

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial by Peters, Solange, Danson, Sarah, Hasan, Baktiar, Dafni, Urania, Reinmuth, Niels, Majem, Margarita, Tournoy, Kurt G, Mark, Michael T, Pless, Miklos, Cobo, Manuel, Rodriguez-Abreu, Delvys, Falchero, Lionel, Moran, Teresa, Ortega Granados, Ana Laura, Monnet, Isabelle, Mohorcic, Katja, Sureda, Bartomeu Massutí, Betticher, Daniel, Demedts, Ingel, Macias, Jose Antionio, Cuffe, Sinead, Luciani, Andrea, Sanchez, Jose Garcia, Curioni-Fontecedro, Alessandra, Gautschi, Oliver, Price, Gillian, Coate, Linda, von Moos, Roger, Zielinski, Christoph, Provencio, Mariano, Menis, Jessica, Ruepp, Barbara, Pochesci, Alessia, Roschitzki-Voser, Heidi, Besse, Benjamin, Rabaglio, Manuela, O'Brien, Mary E R, Stahel, Rolf A

“…Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a…”
Get more information

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer by Nadal, Ernest, Oré-Arce, Martín, Remon, Jordi, Bernabé-Caro, Reyes, Covela-Rúa, Marta, de Castro-Carpeño, Javier, Massutí-Sureda, Bartomeu, Guillot-Morales, Mónica, Majem, Margarita, Maestu-Maiques, Inmaculada, Morilla-Ruíz, Idoia, Gironés, Regina

“…Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and…”
Get full text

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP by Ospina, Aylen Vanessa, Bolufer Nadal, Sergio, Campo-Cañaveral de la Cruz, José Luis, González Larriba, Jose Luis, Macía Vidueira, Ivan, Massutí Sureda, Bartomeu, Nadal, Ernest, Trancho, Florentino Hernando, Álvarez Kindelán, Antonio, Del Barco Morillo, Edel, Bernabé Caro, Reyes, Bosch Barrera, Joaquim, Calvo de Juan, Virginia, Casal Rubio, Joaquin, de Castro, Javier, Cilleruelo Ramos, Ángel, Cobo Dols, Manuel, Dómine Gómez, Manuel, Figueroa Almánzar, Santiago, Garcia Campelo, Rosario, Insa Mollá, Amelia, Jarabo Sarceda, José Ramón, Jiménez Maestre, Unai, López Castro, Rafael, Majem, Margarita, Martinez-Marti, Alex, Martínez Téllez, Elisabeth, Sánchez Lorente, David, Provencio, Mariano

“…Introduction Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the…”
Get full text

Letter to editor response: "Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Controversies and Discussion" by Ospina, Aylen Vanessa, Bolufer Nadal, Sergio, Massuti Sureda, Bartomeu, Provencio, Mariano

Get full text

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study by Valladares-Ayerbes, Manuel, Safont, Maria José, González Flores, Encarnación, García-Alfonso, Pilar, Aranda, Enrique, Muñoz, Ana-Maria López, Falcó Ferrer, Esther, Cirera Nogueras, Luís, Rodríguez-Salas, Nuria, Aparicio, Jorge, Llanos Muñoz, Marta, Pimentel Cáceres, Paola Patricia, Castillo Trujillo, Oscar Alfredo, Vidal Tocino, Rosario, Salgado Fernández, Mercedes, Salud-Salvia, Antonieta, Massuti Sureda, Bartomeu, Garcia-Carbonero, Rocio, Vicente Conesa, Maria Ángeles, Lloansí Vila, Ariadna

“…Purpose RAS ( KRAS / NRAS ) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining…”
Get full text

Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel by De Marinis, Filippo, Eberhardt, Wilfried, Harper, Peter G, Sureda, Bartomeu Massuti, Nackaerts, Kristiaan, Soerensen, Jens Benn, Syrigos, Kostas, Trédaniel, Jean

“…Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases…”
Get more information

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer by Spigel, David R, Dowlati, Afshin, Chen, Yuanbin, Navarro, Alejandro, Yang, James Chih-Hsin, Stojanovic, Goran, Jove, Maria, Rich, Patricia, Andric, Zoran G, Wu, Yi-Long, Rudin, Charles M, Chen, Huanyu, Zhang, Li, Yeung, Stanley, Benzaghou, Fawzi, Paz-Ares, Luis, Bunn, Paul A

“…The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). Patients with SCLC and…”
Get full text

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study by DE CASTRO CARPEÑO, JAVIER, GASCÓN-VILAPLANA, PERE, TEJERINA, ANA MARIA CASAS-FERNÁNDEZ-DE, ANTÓN-TORRES, ANTONIO, LÓPEZ-LÓPEZ, RAFAEL, BARNADAS-MOLINS, AGUSTÍ, CRUZ-HERNÁNDEZ, JUAN JESÚS, MASSUTI-SUREDA, BARTOMEU, CAMPS-HERRERO, CARLOS, ARANDA-AGUILAR, ENRIQUE, LASERNA, FRANCISCO JOSÉ REBOLLO

“…Febrile neutropenia (FN) is one of the most common adverse events associated with myelosuppressive chemotherapy for cancer treatment. The objective of this…”
Get full text

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients by Alberola Candel, Vicente, Carrato Mena, Alfredo, Díaz-Rubio García, Eduardo, Gascón Vilaplana, Pere, González Barón, Manuel, Martín Jiménez, Miguel, Alba Conejo, Emilio, Cassinello Espinosa, Javier, Colomer, Ramon, Cruz Hernández, Juan Jesús, Barnadas i Molins, Agustí, Camps Herrero, Carlos, Casas Fernández de Tejerina, Ana Ma, Carulla Torrent, Joan, Constenla Figueiras, Manuel, Gavilá Gregori, Joaquin, Isla Casado, Ma. Dolores, Massuti Sureda, Bartomeu, Provencio Pulla, Mariano, Rodríguez Sánchez, César Augusto, Sanz Ortiz, Jaime

“…Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic…”
Get full text